Epidyolex for the treatment of Dravet syndrome, a rare and drug-resistant form of epilepsy.
Manufactured by UK pharmaceutical company GW Pharmaceuticals, Epidyolex is a CBD product for children suffering from rare forms of epilepsy, such as Dravet syndrome and Lennox–Gastaut syndrome, which are resistant to conventional medications.
Patients would usually pay more than $24,000 a year for Epidyolex, but will now pay $41.30 per script or $6.60 with a concession card.
Where indicated, I must currently direct them to other PBS-listed products, some of which have already been tried without success or carry unacceptable side effects.
Hospital + Healthcare provides busy hospital, health and aged care professionals with an easy-to-use, readily available source of information, crucial to gaining valuable industry insight.